Ascletis在2025年欧洲皮肤病与性病学会(EADV)大会的突破性研究成果专场中,公布了其首创FASN抑制剂Denifanstat(ASC40)用于痤疮治疗的III期临床研究结果。
Ascletis在2025年欧洲皮肤病与性病学会(EADV)大会的突破性研究成果专场中,公布了其首创FASN抑制剂Denifanstat(ASC40)用于痤疮治疗的III期临床研究结果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.